NOVARTIS AG : Jefferies reiterates its Buy rating
Already positive, the research from Jefferies and its analyst Peter Welford still consider the stock as a Buy opportunity. The target price is unchanged and still at CHF 105. | June 2, 2023
Source: marketscreener.com